Please login to the form below

Not currently logged in

Pfizer’s Elizabeth Barrett joins Novartis as its oncology head

She succeeds Bruno Strigini who retires

Elizabeth BarrettNovartis has appointed Elizabeth Barrett to head up its oncology franchise based at the group’s headquarters in Switzerland.

Barrett, who succeeds Bruno Strigini, has held numerous leadership positions in the pharmaceutical industry as well as in the commercial sector.

She most recently served Pfizer, leading its oncology business but has held several roles with the pharma giant including president, Europe, president North America, speciality care and US president of oncology.

She said: “I feel honoured to join Novartis. It is key to me to contribute to transformative advancements in oncology, and to serve in a highly impactful leadership role to this end.”

Prior to her time with Pfizer, Barrett held roles with Cephalon and Johnson & Johnson.

Vas Narasimhan, chief executive officer at Novartis, said: “Liz is a highly accomplished and recognised oncology and people leader with an impressive record of building successful business organisations in the US.

“She has been instrumental in creating new commercial models, driving innovation in close partnership with research and development and leveraging business development opportunities.

“Her long-time commercial pharma industry experience, marketing skills and perspectives make Liz a great fit to further develop our oncology business.”

12th January 2018

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Redline Strategic

We are a healthcare consultancy, specialising in people and experiences. Using innovative research methods to capture the thoughts of real...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...